Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has issued an announcement.
Cinclus Pharma’s linaprazan glurate has been added to China’s National Reimbursement Drug List for 2025, paving the way for its launch in China in 2026. This inclusion, facilitated by its partner Sinorda and commercialization partner HuaDong Medicine, marks a significant milestone for Cinclus Pharma, enhancing its market presence and providing broader access to GERD treatment in China.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing treatments for acid-related diseases and disorders of the upper gastrointestinal tract. Its leading drug candidate, linaprazan glurate, is designed to treat gastroesophageal reflux disease (GERD) more effectively than current treatments and is backed by extensive clinical research.
Average Trading Volume: 58,123
Technical Sentiment Signal: Buy
Current Market Cap: SEK791.1M
For detailed information about CINPHA stock, go to TipRanks’ Stock Analysis page.